Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1990 4
1992 1
1993 1
1994 3
1995 4
1996 2
1997 2
1998 4
1999 2
2000 5
2001 3
2002 6
2005 2
2006 1
2007 3
2008 2
2010 2
2011 3
2012 1
2014 5
2015 2
2017 2
2018 1
2019 1
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Biochemotherapy of melanoma.
Flaherty LE, Gadgeel SM. Flaherty LE, et al. Semin Oncol. 2002 Oct;29(5):446-55. doi: 10.1053/sonc.2002.35239. Semin Oncol. 2002. PMID: 12407509 Review.
Global urban environmental change drives adaptation in white clover.
Santangelo JS, Ness RW, Cohan B, Fitzpatrick CR, Innes SG, Koch S, Miles LS, Munim S, Peres-Neto PR, Prashad C, Tong AT, Aguirre WE, Akinwole PO, Alberti M, Álvarez J, Anderson JT, Anderson JJ, Ando Y, Andrew NR, Angeoletto F, Anstett DN, Anstett J, Aoki-Gonçalves F, Arietta AZA, Arroyo MTK, Austen EJ, Baena-Díaz F, Barker CA, Baylis HA, Beliz JM, Benitez-Mora A, Bickford D, Biedebach G, Blackburn GS, Boehm MMA, Bonser SP, Bonte D, Bragger JR, Branquinho C, Brans KI, Bresciano JC, Brom PD, Bucharova A, Burt B, Cahill JF, Campbell KD, Carlen EJ, Carmona D, Castellanos MC, Centenaro G, Chalen I, Chaves JA, Chávez-Pesqueira M, Chen XY, Chilton AM, Chomiak KM, Cisneros-Heredia DF, Cisse IK, Classen AT, Comerford MS, Fradinger CC, Corney H, Crawford AJ, Crawford KM, Dahirel M, David S, De Haan R, Deacon NJ, Dean C, Del-Val E, Deligiannis EK, Denney D, Dettlaff MA, DiLeo MF, Ding YY, Domínguez-López ME, Dominoni DM, Draud SL, Dyson K, Ellers J, Espinosa CI, Essi L, Falahati-Anbaran M, Falcão JCF, Fargo HT, Fellowes MDE, Fitzpatrick RM, Flaherty LE, Flood PJ, Flores MF, Fornoni J, Foster AG, Frost CJ, Fuentes TL, Fulkerson JR, Gagnon E, Garbsch F, Garroway CJ, Gerstein AC, Giasson… See abstract for full author list ➔ Santangelo JS, et al. Among authors: flaherty le. Science. 2022 Mar 18;375(6586):1275-1281. doi: 10.1126/science.abk0989. Epub 2022 Mar 17. Science. 2022. PMID: 35298255 Free article.
ACCO: ASCO core curriculum outline.
Muss HB, Von Roenn J, Damon LE, Deangelis LM, Flaherty LE, Harari PM, Kelly K, Kosty MP, Loscalzo MJ, Mennel R, Mitchell BS, Mortimer JE, Muggia F, Perez EA, Pisters PW, Saltz L, Schapira L, Sparano J; American Society of Clinical Oncology. Muss HB, et al. Among authors: flaherty le. J Clin Oncol. 2005 Mar 20;23(9):2049-77. doi: 10.1200/JCO.2005.99.008. Epub 2005 Feb 22. J Clin Oncol. 2005. PMID: 15728218 No abstract available.
Biochemotherapy for melanoma.
Philip PA, Flaherty LE. Philip PA, et al. Among authors: flaherty le. Curr Oncol Rep. 2000 Jul;2(4):314-21. doi: 10.1007/s11912-000-0024-x. Curr Oncol Rep. 2000. PMID: 11122859 Review.
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Tarhini AA, et al. Among authors: flaherty le. J Immunother Cancer. 2021 May;9(5):e002535. doi: 10.1136/jitc-2021-002535. J Immunother Cancer. 2021. PMID: 33963015 Free PMC article. Clinical Trial.
High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE. Samlowski WE, et al. Among authors: flaherty le. Cancer Med. 2017 Nov;6(11):2576-2585. doi: 10.1002/cam4.1223. Epub 2017 Oct 10. Cancer Med. 2017. PMID: 28994212 Free PMC article. Clinical Trial.
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Tarhini AA, et al. Among authors: flaherty le. J Clin Oncol. 2020 Feb 20;38(6):567-575. doi: 10.1200/JCO.19.01381. Epub 2019 Dec 27. J Clin Oncol. 2020. PMID: 31880964 Free PMC article. Clinical Trial.
Adjuvant high-dose interferon revisited.
Sondak VK, Flaherty LE. Sondak VK, et al. Among authors: flaherty le. Cancer J. 2000 May-Jun;6(3):132-4. Cancer J. 2000. PMID: 10882326 Review. No abstract available.
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.
Clark JI, Singh J, Ernstoff MS, Lao CD, Flaherty LE, Logan TF, Curti B, Agarwala SS, Taback B, Cranmer L, Lutzky J, Luna TL, Aung S, Lawson DH. Clark JI, et al. Among authors: flaherty le. J Immunother Cancer. 2018 Jul 27;6(1):76. doi: 10.1186/s40425-018-0387-x. J Immunother Cancer. 2018. PMID: 30053905 Free PMC article. Clinical Trial.
62 results